GlassScriptPhysician profile
Robert Bruce Remler
NPI 1316946114
$2,526.43
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $757 · 2021: $171.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $534.75 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $362.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $280.30 | 2019-2021 | |
| Novo Nordisk INC | $207.29 | 2019-2020 | |
| Pfizer INC. | $147.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $142.39 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $141.80 | 2019-2021 | |
| Allergan, INC. | $70.67 | 2019-2020 | |
| Esperion Therapeutics, INC. | $66.96 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.35 | 2019-2020 | |
| Amarin Pharma, INC. | $56.19 | 2019-2020 | |
| Abbvie INC. | $49.73 | 2021 | |
| Merck Sharp & Dohme LLC | $42.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.97 | 2019-2020 | |
| Astellas Pharma US INC | $32.80 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.49 | 2019-2020 | |
| Boston Scientific Corporation | $29.14 | 2019 | |
| Eisai INC. | $28.62 | 2020 | |
| Horizon Therapeutics Plc | $26.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.83 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $24.34 | 2019 | |
| Lilly USA, LLC | $24.02 | 2019 | |
| Pacira Therapeutics, INC. | $22.91 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.53 | 2019 | |
| Biogen, INC. | $15.07 | 2021 | |
| Radius Health, INC. | $14.89 | 2019 | |
| Mannkind Corporation | $14.19 | 2020 | |
| Sanofi Pasteur INC. | $13.75 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$1,232.11 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Remler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.